ClinVar Miner

Submissions for variant NM_001048174.2(MUTYH):c.397G>C (p.Asp133His)

gnomAD frequency: 0.00010  dbSNP: rs564930066
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129002 SCV000172897 likely pathogenic Hereditary cancer-predisposing syndrome 2024-01-17 criteria provided, single submitter clinical testing The c.481G>C variant (also known as p.D161H), located in coding exon 6 of the MUTYH gene, results from a G to C substitution at nucleotide position 481. The aspartic acid at codon 161 is replaced by histidine, an amino acid with similar properties. This variant has been detected in conjunction with a MUTYH pathogenic variant or as homozygous in multiple unrelated individuals with clinical features of MUTYH-associated disease; however, the phase of the variants from the compound heterozygous cases is unknown (Ambry internal data). This variant was also reported in conjunction with MUTYH p.P405L in a patient with colorectal cancer (Weren RD et al. Nat Genet, 2015 Jun;47:668-71). This alteration has also been reported in prostate and breast cancer cohorts who underwent hereditary multigene panel testing (Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. However, RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). This amino acid position is not well conserved in available vertebrate species. In addition, as a missense substitution this alteration is predicted to be tolerated by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV000204817 SCV000260661 uncertain significance Familial adenomatous polyposis 2 2024-01-09 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 161 of the MUTYH protein (p.Asp161His). This variant is present in population databases (rs564930066, gnomAD 0.05%). This missense change has been observed in individual(s) with breast cancer, clinical features of MUTYH-associated polyposis (MAP), and/or endometrial cancer (PMID: 21424714, 25980754, 27443514, 30093976, 35264596; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 140814). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Counsyl RCV000204817 SCV000487330 uncertain significance Familial adenomatous polyposis 2 2015-12-30 criteria provided, single submitter clinical testing
GeneDx RCV000656908 SCV000565253 uncertain significance not provided 2024-09-04 criteria provided, single submitter clinical testing Co-observed with a MUTYH variant, phase unknown, in a patient with colorectal cancer and polyps (PMID: 25938944; personal communication with authors); Observed in heterozygous state in individuals with polyposis, breast cancer, astrocytoma, endometrial cancer, and prostate cancer (PMID: 30093976, 35264596, 35980532, 27443514, 31970404, 38254803); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 21777424, 25980754, 29684080, 30093976, 33471991, 17161978, Giacomazzi2022[preprint], 35264596, 27443514, 21424714, 25938944, 38254803, 31970404, 35980532)
Mendelics RCV000204817 SCV000837777 uncertain significance Familial adenomatous polyposis 2 2018-07-02 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000656908 SCV000888317 uncertain significance not provided 2022-10-28 criteria provided, single submitter clinical testing The frequency of this variant in the general population, 0.00054 (19/35412 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with colorectal cancer and/or polyposis (PMIDs: 25938944 (2015) and 25980754 (2015)), Cowden Syndrome (PMID: 29684080 (2018)), endometrial cancer (PMID: 27443514 (2016)), prostate cancer (PMID: 30093976 (2018)), breast cancer (PMID: 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)) and pediatric astrocytoma (PMID: 31970404 (2020)). Additionally, the variant has been reported in healthy individuals with no personal or family history of cancer (PMIDs: 21777424 (2011) and 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant.
Color Diagnostics, LLC DBA Color Health RCV000129002 SCV000902780 likely benign Hereditary cancer-predisposing syndrome 2016-03-21 criteria provided, single submitter clinical testing
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000204817 SCV002512304 uncertain significance Familial adenomatous polyposis 2 2021-09-26 criteria provided, single submitter clinical testing ACMG classification criteria: PS4 supporting, PM2 moderate
Sema4, Sema4 RCV000129002 SCV002532293 uncertain significance Hereditary cancer-predisposing syndrome 2021-09-10 criteria provided, single submitter curation
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000481844 SCV002572125 uncertain significance not specified 2022-08-18 criteria provided, single submitter clinical testing Variant summary: MUTYH c.481G>C (p.Asp161His) results in a non-conservative amino acid change located in the HhH-GPD domain (IPR003265) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 250434 control chromosomes, predominantly at a frequency of 0.00055 within the Latino subpopulation in the gnomAD database. This frequency is not higher than estimated for a pathogenic variant in MUTYH causing MUTYH-Associated Polyposis (0.0001 vs 0.0046), allowing no conclusion about variant significance. c.481G>C has been reported in the literature in individuals affected prostate cancer (Chan_2018), suspected lynch syndrome (Yurgelun_2015) without strong evidence for causality. Variant has been reported in a patient with colorectal cancer and a second pathogenic allele p.Y179C (Pitroski_2011). Additionally, the variant has also been reported in breast cancer cases and controls (Dorling_2021). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=9) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance.
Baylor Genetics RCV000204817 SCV004198863 uncertain significance Familial adenomatous polyposis 2 2024-03-17 criteria provided, single submitter clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV000481844 SCV005090620 uncertain significance not specified 2024-07-31 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV004532541 SCV004721531 uncertain significance MUTYH-related disorder 2023-11-20 no assertion criteria provided clinical testing The MUTYH c.481G>C variant is predicted to result in the amino acid substitution p.Asp161His. This variant was reported in individuals with suspected Lynch syndrome, kidney renal clear cell carcinoma, prostate cancer, or breast cancer (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754; Table S7, Yehia et al. 2018. PubMed ID: 29684080; Table S2, Chan et al. 2018. PubMed ID: 30093976; Table S3, Guindalini et al. 2022. PubMed ID: 35264596). This variant was also reported along with an established pathogenic MUTYH variant in an individual with colorectal cancer (Pitroski et al. 2011. PubMed ID: 21424714). This variant is reported in 0.054% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-45798613-C-G) and has conflicting interpretations of pathogenicity in ClinVar ranging from likely benign to uncertain (http://www.ncbi.nlm.nih.gov/clinvar/variation/140814). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.